Andrew S. Boyer - Feb 27, 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Feb 27, 2023
Transactions value $: -$37,923
Form type: 4
Date filed: 3/1/2023, 03:30 PM
Previous filing: Jul 5, 2022
Next filing: Mar 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+31.7K	+15.22%		240K	Feb 27, 2023	Direct	F1, F2
transaction	AMRX	Class A Common Stock	Tax liability	-$37.9K	-17.6K	-7.32%	$2.16	222K	Feb 27, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-31.7K	-50%	$0.00	31.7K	Feb 27, 2023	Class A Common Stock	31.7K		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4	On February 27, 2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Remarks:

Exhibit 24-Power of Attorney